Updates are available Correction dated 2025-02-26

Article History

Received: 14 April 2023

Revised: 19 June 2023

Accepted: 20 June 2023

First Online: 29 July 2023

Change Date: 26 February 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12185-025-03921-5

Declarations

:

: J.N. has received consulting fees from Alexion Pharma, Roche Pharmaceuticals, Chugai Pharmaceuticals, Novartis Pharmaceuticals, Apellis, Biocryst, and Sanofi; and holds patents (or patents are pending) with Roche Pharmaceuticals and Chugai Pharmaceuticals. T.K. has received payment or honoraria from Alexion Pharma. S.I. received support for this manuscript from Alexion Pharma; consulting fees and honoraria for lectures, presentations, and speakers’ bureaus from Alexion Pharma; and served on an advisory board for a post-marketing surveillance for Alexion Pharma. H.M. received support in relation to providing study materials, medical writing, and article processing charges from Alexion Pharma and AstraZeneca Rare Diseases; consulting fees from Alexion Pharma, AstraZeneca Rare Diseases, argenx BVBA, and UCB; lecture fees from Japan Blood Products Organization and Chugai Pharmaceuticals; and served on advisory boards for post-marketing surveillance for Alexion Pharma and AstraZeneca Rare Diseases. T.N. has received lecture fees from Sanofi. S.M. received support in relation to providing study materials, medical writing, and article processing charges from Alexion Pharma; lecture fees from Alexion Pharma; and served on an advisory board for Alexion Pharma. A.S., T.M., Y.F., H.A., and H.H. are employees of and hold stock in Alexion Pharma.